FDA reviewers plan to put Vertex’s cystic fibrosis team to the test on Tuesday. In a review of the big biotech’s data for its closely watched combination therapy for CF, the reviewers raised doubts about the efficacy of the drug, posing a challenge to a program that is crucial to Vertex’s future.

…read more

Source: UPDATED: FDA review challenges Vertex on crucial cystic fibrosis combo data


0 No comments